Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 14/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 1.00 |
| ▸ | CNR2 | P34972 | 1/20 | 1.00 |
| ▸ | PLA2G4A | P47712 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29646274 | 1.00 | FAAH (1.00) | FAAHCNR1CNR2PLA2G4A | |
| SCHEMBL4562549 | 1.00 | FAAH (1.00) | FAAHCNR1CNR2PLA2G4A | |
| SCHEMBL4263058 | 1.00 | FAAH (1.00) | FAAHCNR1CNR2PLA2G4A | |
| SCHEMBL5374409 | 0.95 | FAAH (1.00) | FAAHCNR1CNR2PLA2G4A | |
| SCHEMBL4265721 | 0.93 | FAAH (0.86) | FAAHCNR1CNR2PLA2G4A | |
| SCHEMBL4267077 | 0.93 | FAAH (0.86) | FAAHCNR1CNR2PLA2G4A | |
| SCHEMBL4259045 | 0.93 | FAAH (0.86) | FAAHCNR1CNR2PLA2G4A | |
| SCHEMBL4265190 | 0.90 | FAAH (0.82) | FAAHCNR1CNR2PLA2G4A | |
| SCHEMBL4274325 | 0.90 | FAAH (0.82) | FAAHCNR1CNR2PLA2G4A | |
| SCHEMBL4264010 | 0.90 | FAAH (0.82) | FAAHCNR1CNR2PLA2G4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE39634-E1 | Bisarylimidazoly fatty acid amide hydrolase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-15 | — | — | US | claimed |
| EP-1389107-A4 | BISARYLIMIDAZOLYL FATTY ACID AMIDE HYDROLASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2005-10-12 | — | — | EP | claimed |
| EP-1389107-A1 | BISARYLIMIDAZOLYL FATTY ACID AMIDE HYDROLASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2004-02-18 | — | — | EP | claimed |
| US-6562846-B2 | Bisarylimidazolyl fatty acid amide hydrolase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-05-13 | — | — | US | claimed |
| US-20020188009-A1 | Bisarylimidazolyl fatty acid amide hydrolase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2002-12-12 | — | — | US | claimed |
| WO-2002087569-A1 | BISARYLIMIDAZOLYL FATTY ACID AMIDE HYDROLASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-11-07 | — | — | WO | claimed |
| EP-2937341-B1 | 4-(BENZYL)-PIPERAZINE-1-CARBOXYLIC ACID PHENYLAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE (FAAH) FOR THE TREATMENT OF ANXIETY, PAIN AND OTHER CONDITIONS | JANSSEN PHARMACEUTICA NV (BE) | 2017-07-05 | — | — | EP | disclosed |
| US-9688664-B2 | Modulators of fatty acid amide hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-27 | — | — | US | disclosed |
| EP-2937341-A1 | 4-(BENZYL)-PIPERAZINE-1-CARBOXYLIC ACID PHENYLAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE (FAAH) FOR THE TREATMENT OF ANXIETY, PAIN AND OTHER CONDITIONS | Janssen Pharmaceutica N.V. (BE) | 2015-10-28 | — | — | EP | disclosed |
| US-9169224-B2 | Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-27 | — | — | US | disclosed |
| US-20150099761-A1 | MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (US) | 2015-04-09 | — | — | US | disclosed |
| US-8987312-B2 | Alpha-keto heterocycles as FAAH inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-03-24 | — | — | US | disclosed |
| US-8940745-B2 | Modulators of fatty acid amide hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-27 | — | — | US | disclosed |
| WO-2006116773-A2 | METHODS, COMPOSITIONS, AND COMPOUNDS FOR MODULATION OF MONOACYLGLYCEROL LIPASE, PAIN, AND STRESS-RELATED DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-11-02 | — | — | WO | disclosed |
| WO-2005115370-A2 | COMPOUNDS AND METHODS FOR TREATING NON-INFLAMMATORY PAIN USING PPARALPHA AGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-12-08 | — | — | WO | disclosed |
| EP-1389107-A4 | BISARYLIMIDAZOLYL FATTY ACID AMIDE HYDROLASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2005-10-12 | — | — | EP | disclosed |
| EP-1389107-A1 | BISARYLIMIDAZOLYL FATTY ACID AMIDE HYDROLASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2004-02-18 | — | — | EP | disclosed |
| US-6562846-B2 | Bisarylimidazolyl fatty acid amide hydrolase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-05-13 | — | — | US | disclosed |
| US-20020188009-A1 | Bisarylimidazolyl fatty acid amide hydrolase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2002-12-12 | — | — | US | disclosed |
| WO-2002087569-A1 | BISARYLIMIDAZOLYL FATTY ACID AMIDE HYDROLASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099761-A1 | MODULATORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, APEH | FAAH 1/4885CNR1 12/4885CNR2 5/4885 |
| US-20020188009-A1 | Bisarylimidazolyl fatty acid amide hydrolase inhibitors | FAAH, FAAH2, FASN | FAAH 1/4885CNR1 172/4885CNR2 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.